These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17401423)

  • 1. p53 alterations in human cancer: more questions than answers.
    Soussi T
    Oncogene; 2007 Apr; 26(15):2145-56. PubMed ID: 17401423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When mutant p53 plays hide and seek: a new challenge for diagnosis and therapy?
    Soussi T; Hjortsberg L
    Trends Mol Med; 2009 Jan; 15(1):1-4. PubMed ID: 19097939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of mutant p53 in human cancer.
    Goh AM; Coffill CR; Lane DP
    J Pathol; 2011 Jan; 223(2):116-26. PubMed ID: 21125670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulated mRNA expression of ASPP and the hypermethylation of the 5'-untranslated region in cancer cell lines retaining wild-type p53.
    Liu ZJ; Lu X; Zhang Y; Zhong S; Gu SZ; Zhang XB; Yang X; Xin HM
    FEBS Lett; 2005 Mar; 579(7):1587-90. PubMed ID: 15757645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse models with modified p53 sequences to study cancer and ageing.
    Clarke AR; Hollstein M
    Cell Death Differ; 2003 Apr; 10(4):443-50. PubMed ID: 12719721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcription regulation by mutant p53.
    Weisz L; Oren M; Rotter V
    Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53: an oncogenic transcription factor.
    Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
    Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of mutant p53 with DNA: guilt by association.
    Kim E; Deppert W
    Oncogene; 2007 Apr; 26(15):2185-90. PubMed ID: 17401427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
    Selivanova G; Wiman KG
    Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 mutation heterogeneity in cancer.
    Soussi T; Lozano G
    Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What have animal models taught us about the p53 pathway?
    Lozano G; Zambetti GP
    J Pathol; 2005 Jan; 205(2):206-20. PubMed ID: 15643668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASPP [corrected] and cancer.
    Trigiante G; Lu X
    Nat Rev Cancer; 2006 Mar; 6(3):217-26. PubMed ID: 16498444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ASPP proteins complex and cooperate with p300 to modulate the transcriptional activity of p53.
    Gillotin S; Lu X
    FEBS Lett; 2011 Jun; 585(12):1778-82. PubMed ID: 21513714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression.
    Farrell GC; Larter CZ; Hou JY; Zhang RH; Yeh MM; Williams J; dela Pena A; Francisco R; Osvath SR; Brooling J; Teoh N; Sedger LM
    J Gastroenterol Hepatol; 2009 Mar; 24(3):443-52. PubMed ID: 19226377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of ANKRD11 as a p53 coactivator.
    Neilsen PM; Cheney KM; Li CW; Chen JD; Cawrse JE; Schulz RB; Powell JA; Kumar R; Callen DF
    J Cell Sci; 2008 Nov; 121(Pt 21):3541-52. PubMed ID: 18840648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53--a natural cancer killer: structural insights and therapeutic concepts.
    Römer L; Klein C; Dehner A; Kessler H; Buchner J
    Angew Chem Int Ed Engl; 2006 Oct; 45(39):6440-60. PubMed ID: 16983711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant p53: the loaded gun.
    Selivanova G
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1136-41. PubMed ID: 11892926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
    Bon G; Di Carlo SE; Folgiero V; Avetrani P; Lazzari C; D'Orazi G; Brizzi MF; Sacchi A; Soddu S; Blandino G; Mottolese M; Falcioni R
    Cancer Res; 2009 Jul; 69(14):5978-86. PubMed ID: 19567674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.